Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

A Single Monoclonal Antibody against the Peanut Allergen Ara h 2 Protects against Systemic and Local Peanut Allergy.

Storni F, Cabral-Miranda G, Roesti E, Zha L, Engeroff P, Zeltins A, Cragg M, Vogel M, Bachmann MF.

Int Arch Allergy Immunol. 2020 Mar 10:1-8. doi: 10.1159/000505917. [Epub ahead of print]

2.

Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial.

Blakemore SJ, Clifford R, Parker H, Antoniou P, Stec-Dziedzic E, Larrayoz M, Davis Z, Kadalyayil L, Colins A, Robbe P, Vavoulis D, Forster J, Carr L, Morilla R, Else M, Bryant D, McCarthy H, Walewska RJ, Steele AJ, Chan J, Speight G, Stankovic T, Cragg MS, Catovsky D, Oscier DG, Rose-Zerilli MJJ, Schuh A, Strefford JC.

Leukemia. 2020 Feb 3. doi: 10.1038/s41375-020-0723-2. [Epub ahead of print]

PMID:
32015491
3.

Signaling through the Inhibitory Fc Receptor FcγRIIB Induces CD8+ T Cell Apoptosis to Limit T Cell Immunity.

Morris AB, Farley CR, Pinelli DF, Adams LE, Cragg MS, Boss JM, Scharer CD, Fribourg M, Cravedi P, Heeger PS, Ford ML.

Immunity. 2020 Jan 14;52(1):136-150.e6. doi: 10.1016/j.immuni.2019.12.006.

PMID:
31940267
4.

Vaccine against peanut allergy based on engineered virus-like particles displaying single major peanut allergens.

Storni F, Zeltins A, Balke I, Heath MD, Kramer MF, Skinner MA, Zha L, Roesti E, Engeroff P, Muri L, von Werdt D, Gruber T, Cragg M, Mlynarczyk M, Kündig TM, Vogel M, Bachmann MF.

J Allergy Clin Immunol. 2019 Dec 19. pii: S0091-6749(19)31709-9. doi: 10.1016/j.jaci.2019.12.007. [Epub ahead of print]

5.

Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells.

Lemm EA, Valle-Argos B, Smith LD, Richter J, Gebreselassie Y, Carter MJ, Karolova J, Svaton M, Helman K, Weston-Bell NJ, Karydis L, Williamson CT, Lenz G, Pettigrew J, Harwig C, Stevenson FK, Cragg M, Forconi F, Steele AJ, Cross J, Mackenzie L, Klener P, Packham G.

Clin Cancer Res. 2020 Apr 1;26(7):1700-1711. doi: 10.1158/1078-0432.CCR-19-2202. Epub 2019 Dec 12.

PMID:
31831562
6.

BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia.

Smith LD, Minton AR, Blunt MD, Karydis LI, Dutton DA, Rogers-Broadway KR, Dobson R, Liu R, Norster F, Hogg E, Ashton-Key M, Strefford JC, Jia L, Efremov DG, Helgason GV, Johnson PWM, Stevenson FK, Forconi F, Cragg MS, Tumbarello DA, Packham G, Steele AJ.

Leukemia. 2020 Feb;34(2):640-644. doi: 10.1038/s41375-019-0557-y. Epub 2019 Aug 28. No abstract available.

7.

Cyclophosphamide Enhances Cancer Antibody Immunotherapy in the Resistant Bone Marrow Niche by Modulating Macrophage FcγR Expression.

Roghanian A, Hu G, Fraser C, Singh M, Foxall RB, Meyer MJ, Lees E, Huet H, Glennie MJ, Beers SA, Lim SH, Ashton-Key M, Thirdborough SM, Cragg MS, Chen J.

Cancer Immunol Res. 2019 Nov;7(11):1876-1890. doi: 10.1158/2326-6066.CIR-18-0835. Epub 2019 Aug 26.

PMID:
31451483
8.

When Three Isn't a Crowd: A Digyny Concept for Treatment-Resistant, Near-Triploid Human Cancers.

Salmina K, Gerashchenko BI, Hausmann M, Vainshelbaum NM, Zayakin P, Erenpreiss J, Freivalds T, Cragg MS, Erenpreisa J.

Genes (Basel). 2019 Jul 19;10(7). pii: E551. doi: 10.3390/genes10070551. Review.

9.

Cartilage-binding antibodies induce pain through immune complex-mediated activation of neurons.

Bersellini Farinotti A, Wigerblad G, Nascimento D, Bas DB, Morado Urbina C, Nandakumar KS, Sandor K, Xu B, Abdelmoaty S, Hunt MA, Ängeby Möller K, Baharpoor A, Sinclair J, Jardemark K, Lanner JT, Khmaladze I, Borm LE, Zhang L, Wermeling F, Cragg MS, Lengqvist J, Chabot-Doré AJ, Diatchenko L, Belfer I, Collin M, Kultima K, Heyman B, Jimenez-Andrade JM, Codeluppi S, Holmdahl R, Svensson CI.

J Exp Med. 2019 Aug 5;216(8):1904-1924. doi: 10.1084/jem.20181657. Epub 2019 Jun 13.

10.

Impact of Human FcγR Gene Polymorphisms on IgG-Triggered Cytokine Release: Critical Importance of Cell Assay Format.

Hussain K, Hargreaves CE, Rowley TF, Sopp JM, Latham KV, Bhatta P, Sherington J, Cutler RM, Humphreys DP, Glennie MJ, Strefford JC, Cragg MS.

Front Immunol. 2019 Mar 7;10:390. doi: 10.3389/fimmu.2019.00390. eCollection 2019.

11.

The Cancer Aneuploidy Paradox: In the Light of Evolution.

Salmina K, Huna A, Kalejs M, Pjanova D, Scherthan H, Cragg MS, Erenpreisa J.

Genes (Basel). 2019 Jan 25;10(2). pii: E83. doi: 10.3390/genes10020083.

12.

Antibodies to Costimulatory Receptor 4-1BB Enhance Anti-tumor Immunity via T Regulatory Cell Depletion and Promotion of CD8 T Cell Effector Function.

Buchan SL, Dou L, Remer M, Booth SG, Dunn SN, Lai C, Semmrich M, Teige I, Mårtensson L, Penfold CA, Chan HTC, Willoughby JE, Mockridge CI, Dahal LN, Cleary KLS, James S, Rogel A, Kannisto P, Jernetz M, Williams EL, Healy E, Verbeek JS, Johnson PWM, Frendéus B, Cragg MS, Glennie MJ, Gray JC, Al-Shamkhani A, Beers SA.

Immunity. 2018 Nov 20;49(5):958-970.e7. doi: 10.1016/j.immuni.2018.09.014. Epub 2018 Nov 13.

13.

Immunological Methods to Study Monoclonal Antibody Activity in Chronic Lymphocytic Leukaemia.

Carter MJ, Dahal LN, Cleary KLS, Marshall MJE, French RR, Beers SA, Cragg MS.

Methods Mol Biol. 2019;1881:173-184. doi: 10.1007/978-1-4939-8876-1_14.

PMID:
30350206
14.

Evaluating Anti-CD32b F(ab) Conformation Using Molecular Dynamics and Small-Angle X-Ray Scattering.

Sutton EJ, Bradshaw RT, Orr CM, Frendéus B, Larsson G, Teige I, Cragg MS, Tews I, Essex JW.

Biophys J. 2018 Jul 17;115(2):289-299. doi: 10.1016/j.bpj.2018.03.040.

15.

Deleting Malignant B Cells With Second-Generation Anti-CD20 Antibodies.

Sopp J, Cragg MS.

J Clin Oncol. 2018 Aug 1;36(22):2323-2325. doi: 10.1200/JCO.2018.78.7390. Epub 2018 Jun 12. No abstract available.

PMID:
29894272
16.

Through the barricades: overcoming the barriers to effective antibody-based cancer therapeutics.

Dalziel M, Beers SA, Cragg MS, Crispin M.

Glycobiology. 2018 Sep 1;28(9):697-712. doi: 10.1093/glycob/cwy043. Review.

PMID:
29800150
17.

UC-1V150, a potent TLR7 agonist capable of activating macrophages and potentiating mAb-mediated target cell deletion.

Dahal LN, Gadd A, Edwards AD, Cragg MS, Beers SA.

Scand J Immunol. 2018 Jun;87(6):e12666. doi: 10.1111/sji.12666. Epub 2018 May 6.

18.

Complex Interplay between Epitope Specificity and Isotype Dictates the Biological Activity of Anti-human CD40 Antibodies.

Yu X, Chan HTC, Orr CM, Dadas O, Booth SG, Dahal LN, Penfold CA, O'Brien L, Mockridge CI, French RR, Duriez P, Douglas LR, Pearson AR, Cragg MS, Tews I, Glennie MJ, White AL.

Cancer Cell. 2018 Apr 9;33(4):664-675.e4. doi: 10.1016/j.ccell.2018.02.009. Epub 2018 Mar 22.

19.

New Zealand's revised Ethnicity Data Protocols must not become a shelved document: a challenge from Hei Āhuru Mōwai.

Gurney JK, Scott N, Thompson G, Turner S, Anson J, Cragg M, Doherty J, Wall M, Laking G, Moke T, Blundell R, Coote P.

N Z Med J. 2018 Feb 23;131(1470):104-106. No abstract available.

PMID:
29470482
20.

The PI3Kδ-Selective Inhibitor Idelalisib Minimally Interferes with Immune Effector Function Mediated by Rituximab or Obinutuzumab and Significantly Augments B Cell Depletion In Vivo.

Palazzo A, Herter S, Grosmaire L, Jones R, Frey CR, Limani F, Bacac M, Umana P, Oldham RJ, Marshall MJE, Cox KL, Turaj AH, Cragg MS, Klein C, Carter MJ, Tannheimer S.

J Immunol. 2018 Apr 1;200(7):2304-2312. doi: 10.4049/jimmunol.1700323. Epub 2018 Feb 16.

21.

New revelations from an old receptor: Immunoregulatory functions of the inhibitory Fc gamma receptor, FcγRIIB (CD32B).

Roghanian A, Stopforth RJ, Dahal LN, Cragg MS.

J Leukoc Biol. 2018 Feb 6. doi: 10.1002/JLB.2MIR0917-354R. [Epub ahead of print] Review.

PMID:
29406570
22.

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking.

Turaj AH, Cox KL, Penfold CA, French RR, Mockridge CI, Willoughby JE, Tutt AL, Griffiths J, Johnson PWM, Glennie MJ, Levy R, Cragg MS, Lim SH.

Sci Rep. 2018 Feb 2;8(1):2278. doi: 10.1038/s41598-018-20656-y.

23.

An unexpected protective role of low-affinity allergen-specific IgG through the inhibitory receptor FcγRIIb.

Zha L, Leoratti FMS, He L, Mohsen MO, Cragg M, Storni F, Vogel M, Bachmann MF.

J Allergy Clin Immunol. 2018 Nov;142(5):1529-1536.e6. doi: 10.1016/j.jaci.2017.09.054. Epub 2018 Jan 31.

PMID:
29391255
24.

Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation.

Johnston HE, Carter MJ, Larrayoz M, Clarke J, Garbis SD, Oscier D, Strefford JC, Steele AJ, Walewska R, Cragg MS.

Mol Cell Proteomics. 2018 Apr;17(4):776-791. doi: 10.1074/mcp.RA117.000539. Epub 2018 Jan 24.

25.

Detection of Experimental and Clinical Immune Complexes by Measuring SHIP-1 Recruitment to the Inhibitory FcγRIIB.

Stopforth RJ, Oldham RJ, Tutt AL, Duriez P, Chan HTC, Binkowski BF, Zimprich C, Li D, Hargreaves PG, Cong M, Reddy V, Leandro MJ, Cambridge G, Lux A, Nimmerjahn F, Cragg MS.

J Immunol. 2018 Mar 1;200(5):1937-1950. doi: 10.4049/jimmunol.1700832. Epub 2018 Jan 19.

26.

Antibody Tumor Targeting Is Enhanced by CD27 Agonists through Myeloid Recruitment.

Turaj AH, Hussain K, Cox KL, Rose-Zerilli MJJ, Testa J, Dahal LN, Chan HTC, James S, Field VL, Carter MJ, Kim HJ, West JJ, Thomas LJ, He LZ, Keler T, Johnson PWM, Al-Shamkhani A, Thirdborough SM, Beers SA, Cragg MS, Glennie MJ, Lim SH.

Cancer Cell. 2017 Dec 11;32(6):777-791.e6. doi: 10.1016/j.ccell.2017.11.001. Epub 2017 Nov 30.

27.

Therapeutic Antibodies: What Have We Learnt from Targeting CD20 and Where Are We Going?

Marshall MJE, Stopforth RJ, Cragg MS.

Front Immunol. 2017 Oct 4;8:1245. doi: 10.3389/fimmu.2017.01245. eCollection 2017. Review.

28.

Lamin B1 regulates somatic mutations and progression of B-cell malignancies.

Klymenko T, Bloehdorn J, Bahlo J, Robrecht S, Akylzhanova G, Cox K, Estenfelder S, Wang J, Edelmann J, Strefford JC, Wojdacz TK, Fischer K, Hallek M, Stilgenbauer S, Cragg M, Gribben J, Braun A.

Leukemia. 2018 Feb;32(2):364-375. doi: 10.1038/leu.2017.255. Epub 2017 Aug 14.

29.

TLR-3/9 Agonists Synergize with Anti-ErbB2 mAb-Letter.

Turaj AH, Dahal LN, Beers SA, Cragg MS, Lim SH.

Cancer Res. 2017 Jun 15;77(12):3376-3378. doi: 10.1158/0008-5472.CAN-17-0412. Epub 2017 Jun 5. No abstract available.

30.

Anti-FcγRIIB (CD32) Antibodies Differentially Modulate Murine FVIII-Specific Recall Response in vitro.

Vollack N, Friese J, Bergmann S, Cragg MS, Tiede A, Werwitzke S.

Scand J Immunol. 2017 Aug;86(2):91-99. doi: 10.1111/sji.12573.

31.

STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Dahal LN, Dou L, Hussain K, Liu R, Earley A, Cox KL, Murinello S, Tracy I, Forconi F, Steele AJ, Duriez PJ, Gomez-Nicola D, Teeling JL, Glennie MJ, Cragg MS, Beers SA.

Cancer Res. 2017 Jul 1;77(13):3619-3631. doi: 10.1158/0008-5472.CAN-16-2784. Epub 2017 May 16.

32.

Improving Antibody-Based Cancer Therapeutics Through Glycan Engineering.

Yu X, Marshall MJE, Cragg MS, Crispin M.

BioDrugs. 2017 Jun;31(3):151-166. doi: 10.1007/s40259-017-0223-8. Review.

PMID:
28466278
33.

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity.

Lohse S, Loew S, Kretschmer A, Jansen JHM, Meyer S, Ten Broeke T, Rösner T, Dechant M, Derer S, Klausz K, Kellner C, Schwanbeck R, French RR, Tipton TRW, Cragg MS, Schewe DM, Peipp M, Leusen JHW, Valerius T.

Br J Haematol. 2018 May;181(3):413-417. doi: 10.1111/bjh.14624. Epub 2017 Apr 27. No abstract available.

PMID:
28449349
34.

Obinutuzumab induces superior B-cell cytotoxicity to rituximab in rheumatoid arthritis and systemic lupus erythematosus patient samples.

Reddy V, Klein C, Isenberg DA, Glennie MJ, Cambridge G, Cragg MS, Leandro MJ.

Rheumatology (Oxford). 2017 Jul 1;56(7):1227-1237. doi: 10.1093/rheumatology/kex067.

35.

Antibody Distance from the Cell Membrane Regulates Antibody Effector Mechanisms.

Cleary KLS, Chan HTC, James S, Glennie MJ, Cragg MS.

J Immunol. 2017 May 15;198(10):3999-4011. doi: 10.4049/jimmunol.1601473. Epub 2017 Apr 12.

36.

Development of a T-cell Receptor Mimic Antibody against Wild-Type p53 for Cancer Immunotherapy.

Li D, Bentley C, Anderson A, Wiblin S, Cleary KLS, Koustoulidou S, Hassanali T, Yates J, Greig J, Nordkamp MO, Trenevska I, Ternette N, Kessler BM, Cornelissen B, Cragg MS, Banham AH.

Cancer Res. 2017 May 15;77(10):2699-2711. doi: 10.1158/0008-5472.CAN-16-3247. Epub 2017 Mar 31.

37.
38.

OX40: Structure and function - What questions remain?

Willoughby J, Griffiths J, Tews I, Cragg MS.

Mol Immunol. 2017 Mar;83:13-22. doi: 10.1016/j.molimm.2017.01.006. Epub 2017 Jan 13. Review.

PMID:
28092803
39.

Coupled Proliferation and Apoptosis Maintain the Rapid Turnover of Microglia in the Adult Brain.

Askew K, Li K, Olmos-Alonso A, Garcia-Moreno F, Liang Y, Richardson P, Tipton T, Chapman MA, Riecken K, Beccari S, Sierra A, Molnár Z, Cragg MS, Garaschuk O, Perry VH, Gomez-Nicola D.

Cell Rep. 2017 Jan 10;18(2):391-405. doi: 10.1016/j.celrep.2016.12.041.

40.

Integrated Cellular and Plasma Proteomics of Contrasting B-cell Cancers Reveals Common, Unique and Systemic Signatures.

Johnston HE, Carter MJ, Cox KL, Dunscombe M, Manousopoulou A, Townsend PA, Garbis SD, Cragg MS.

Mol Cell Proteomics. 2017 Mar;16(3):386-406. doi: 10.1074/mcp.M116.063511. Epub 2017 Jan 4.

41.

PI3Kδ inhibition elicits anti-leukemic effects through Bim-dependent apoptosis.

Carter MJ, Cox KL, Blakemore SJ, Turaj AH, Oldham RJ, Dahal LN, Tannheimer S, Forconi F, Packham G, Cragg MS.

Leukemia. 2017 Jun;31(6):1423-1433. doi: 10.1038/leu.2016.333. Epub 2016 Nov 15.

42.

Genomic disruption of the histone methyltransferase SETD2 in chronic lymphocytic leukaemia.

Parker H, Rose-Zerilli MJ, Larrayoz M, Clifford R, Edelmann J, Blakemore S, Gibson J, Wang J, Ljungström V, Wojdacz TK, Chaplin T, Roghanian A, Davis Z, Parker A, Tausch E, Ntoufa S, Ramos S, Robbe P, Alsolami R, Steele AJ, Packham G, Rodríguez-Vicente AE, Brown L, McNicholl F, Forconi F, Pettitt A, Hillmen P, Dyer M, Cragg MS, Chelala C, Oakes CC, Rosenquist R, Stamatopoulos K, Stilgenbauer S, Knight S, Schuh A, Oscier DG, Strefford JC.

Leukemia. 2016 Nov;30(11):2179-2186. doi: 10.1038/leu.2016.134. Epub 2016 May 20.

43.

Detection of candidate biomarkers of prostate cancer progression in serum: a depletion-free 3D LC/MS quantitative proteomics pilot study.

Larkin SE, Johnston HE, Jackson TR, Jamieson DG, Roumeliotis TI, Mockridge CI, Michael A, Manousopoulou A, Papachristou EK, Brown MD, Clarke NW, Pandha H, Aukim-Hastie CL, Cragg MS, Garbis SD, Townsend PA.

Br J Cancer. 2016 Oct 25;115(9):1078-1086. doi: 10.1038/bjc.2016.291. Epub 2016 Sep 29.

44.

FcγRIIB-Independent Mechanisms Controlling Membrane Localization of the Inhibitory Phosphatase SHIP in Human B Cells.

Pauls SD, Ray A, Hou S, Vaughan AT, Cragg MS, Marshall AJ.

J Immunol. 2016 Sep 1;197(5):1587-96. doi: 10.4049/jimmunol.1600105. Epub 2016 Jul 25.

45.

Optimising B-cell depletion in autoimmune disease: is obinutuzumab the answer?

Reddy V, Dahal LN, Cragg MS, Leandro M.

Drug Discov Today. 2016 Aug;21(8):1330-8. doi: 10.1016/j.drudis.2016.06.009. Epub 2016 Jun 22. Review.

PMID:
27343722
46.

Death by a thousand knives: Multiple BH3-only proteins are required for maximal apoptosis triggered through the BCR.

Carter MJ, Cragg MS.

Mol Cell Oncol. 2015 Aug 27;3(2):e1084444. doi: 10.1080/23723556.2015.1084444. eCollection 2016 Mar.

47.

IgG subclasses determine pathways of anaphylaxis in mice.

Beutier H, Gillis CM, Iannascoli B, Godon O, England P, Sibilano R, Reber LL, Galli SJ, Cragg MS, Van Rooijen N, Mancardi DA, Bruhns P, Jönsson F.

J Allergy Clin Immunol. 2017 Jan;139(1):269-280.e7. doi: 10.1016/j.jaci.2016.03.028. Epub 2016 Apr 26.

48.

Resistance is futile: Targeting the inhibitory FcγRIIB (CD32B) to maximize immunotherapy.

Roghanian A, Cragg MS, Frendéus B.

Oncoimmunology. 2015 Aug 12;5(2):e1069939. eCollection 2016 Feb.

49.

Correction: Evaluation of High-Throughput Genomic Assays for the Fc Gamma Receptor Locus.

Hargreaves CE, Iriyama C, Rose-Zerilli MJ, Nagelkerke SQ, Hussain K, Ganderton R, Lee C, Machado LR, Hollox EJ, Parker H, Latham KV, Kuijpers TW, Potter KN, Coupland SE, Davies A, Stackpole M, Oates M, Pettitt AR, Glennie MJ, Cragg MS, Strefford JC.

PLoS One. 2016 Mar 23;11(3):e0145040. doi: 10.1371/journal.pone.0145040. eCollection 2016. No abstract available.

50.

IL-4 enhances expression and function of surface IgM in CLL cells.

Aguilar-Hernandez MM, Blunt MD, Dobson R, Yeomans A, Thirdborough S, Larrayoz M, Smith LD, Linley A, Strefford JC, Davies A, Johnson PM, Savelyeva N, Cragg MS, Forconi F, Packham G, Stevenson FK, Steele AJ.

Blood. 2016 Jun 16;127(24):3015-25. doi: 10.1182/blood-2015-11-682906. Epub 2016 Mar 21.

PMID:
27002119

Supplemental Content

Support Center